Objectives: Reduced susceptibility to extended-spectrum cephalosporins in Neisseria gonorrhoeae has, to date, been associated with three alterations: a mosaic penA allele encoding the penicillin-binding protein 2 (PBP2); A-del-mtrR, an adenine deletion in the mtrR promoter; and penB, comprising mutated alleles of PorBIb. In this study, we examined an association between reduced susceptibility to ceftriaxone and additional mutations in gonococcal PBP2.
Introduction
A progressive loss of efficacy of the penicillins, quinolones and other antibiotics has seen the extended-spectrum cephalosporins (ESCs) form the basis of standard regimens for the treatment of gonorrhoea in many countries. Recently, however, there have been increasing numbers of reports of gonococci with decreased in vitro susceptibility to ESCs, in addition to instances of documented treatment failures of genital tract gonorrhoea using oral ESCs in Japan and Hong Kong. 1 -3 Research into gonococcal ESC resistance determinants has, to date, been focused on three key alterations: (i) a mosaic penA allele, a principal alteration of interest, which is thought to result from the recombination of penA sequences from various Neisseria species-penA encodes the penicillin-binding protein 2 (PBP2), the primary lethal target of b-lactam antibiotics; (ii) A-del-mtrR, an adenine deletion in the promoter region of mtrR, a transcriptional repressor that regulates expression of the MtrC-MtrD-MtrE efflux pump; and (iii) penB, which encodes mutated alleles at amino acids 120 and 121 of the major 2 -8 In vitro experiments have further shown that a combination of these genetic changes is required to achieve the higher MICs observed in clinical isolates and that each alteration has differential effects on the response to various ESCs. 7 However, it is clear that other as yet unidentified lesions are involved in ESC resistance and that the mosaic penA sequence, either alone or in conjunction with A-del-mtrR and penB, does not account for a considerable proportion of the reduced susceptibility to ESCs observed in gonococci, including those isolated in Australia 5 and, more recently, Korea. 8 We previously reported a highly significant association between reduced susceptibility to ceftriaxone and substitutions at amino acid 501 in the PBP2 protein (A501V and A501T), suggesting that spontaneous single nucleotide polymorphisms in the penA gene (in addition to mosaicism) may also account for reduced susceptibility to ceftriaxone. 5 A recent study of gonococci with raised MICs of ceftriaxone in Sydney showed that a high proportion of the isolates examined did not contain a mosaic penA allele. 9 We examined these strains further in this study and reanalysed earlier data to report here an association between reduced susceptibility to ceftriaxone and two additional mutations in the PBP2 protein at amino acids 542 and 551.
Materials and methods
The first part of the study involved identifying mutations of interest in a previously assembled group of N. gonorrhoeae isolates with raised MICs of ceftriaxone. We then further explored the association of these mutations with MIC level in another existing N. gonorrhoeae isolate sample set representing a broad range of both ceftriaxone and penicillin MIC values.
We identified 76 N. gonorrhoeae isolates, from a previous study (specimens collected in Sydney, Australia, 2007 -08), 9 lacking the mosaic penA sequence and with previously determined reduced susceptibility to ceftriaxone, having MICs of 0.016 mg/L (n¼36), 0.03 mg/L (n ¼39) and 0.06 mg/L (n¼1) (see Table 1 ). These were tested for mutations A-del-mtrR and penB, as well as substitutions at positions 501, 542 and 551 in the PBP2 protein using a previously described SYBR Green-based real-time PCR approach combining heat-denatured isolates with either high-resolution melting curve (HRM) analysis or allelespecific PCR (ASP). 10 Briefly, the A-del-mtrR ASP and penB HRM methods were performed as previously described, except that the Qiagen Quantitect SYBR kit (Qiagen, Australia) was used as the basis of the reaction mixture. This penB HRM method can readily distinguish the key amino acid substations 'KD' (G120K and A121D), as well 'KG', 'KN' and 'NA' at positions 120 and 121 of PorBIb, but cannot distinguish 'GA', 'DA' and 'GS' because of their similar GC contents.
10 PBP2 mutations were investigated by HRM using primers designed as part of this study to flank the first two nucleotides of each codon for single amino acid substitutions 501 (CGGCGCTAAAACCGGTACG and GCCATTGACCAGTTTGCGC), 542 (CGACGAACCGACTGCCCAC and GCCACTACGCCGCCGTAATAG) and 551 (GGCGGCGTAGTGGCAGGG and CCGCCCATAATTTTTTTGAAGGGC).
PBP2 substitutions 542 and 551 were further investigated by reanalysing penA sequence data obtained from a previous study of 109 gonococci, 5 selected on the basis of their diverse temporal and geographical origins, and exhibiting a range of ceftriaxone MICs, as previously described (see Table 2 ). For these investigations, isolates harbouring mosaic penA (n¼11) were excluded from the calculations, leaving a total of 98 isolates. Two sample, two-sided tests of proportion were used to identify any statistical association between ceftriaxone and penicillin MIC categories and the presence of 542 and 551 mutations, with a P value of ,0.05 considered significant. MICs were categorized as either ≤0.008 mg/L (susceptible) or ≥0.016 mg/L (reduced susceptibility) for ceftriaxone and either ≤0.5 mg/L (susceptible/less susceptible) or ≥1 mg/L for penicillin (resistant). Comparisons were performed using Stata version 10 (StataCorp, College Station, TX, USA).
Results
Of the 76 N. gonorrhoeae isolates exhibiting reduced susceptibility to ceftriaxone and lacking the mosaic penA sequence (Sydney, 2007-08), an amino acid substitution was detected using HRM at PBP2 position 551 for 26 isolates, position 542 for 39 isolates and position 501 for 9 isolates. These included eight isolates for which one or more of these mutations were observed. Notably, there were 12 isolates in which one of the 501, 542 and 551 mutations was not observed. The A-del-mtrR mutation was present in 63/76 isolates and a range of penB mutations was observed, with the recognized 'KD' mutation being the most prevalent in 49/76 isolates ( Table 1) .
Analyses of the 98 gonococcal isolates from a previous study 5 of gonococcal penA sequences showed that substitutions at positions 542 and 551 were significantly associated with raised MICs to both ceftriaxone and penicillin. Of 98 isolates, changes at position 551 (P551S or P551L) were observed in 11/37 gonococci with ceftriaxone MICs ≤0.008 mg/L and in 39/61 gonococci with ceftriaxone MICs ≥0.016 mg/L (P ¼ 0.001), and alterations at position 542 (G542S) were observed in 3/37 and 17/61 isolates, respectively (P¼ 0.0186) ( Table 2 ). For penicillin, changes at position 551 (P551S or P551L) were observed in 5/24 Whiley et al.
gonococci with penicillin MICs ≤0.5 mg/L and in 45/74 gonococci with penicillin MICs ≥1 mg/L (P ¼ 0.0007), and alterations at position 542 (G542S) were observed in 1/24 and 19/74 isolates, respectively (P¼ 0.0231) ( Table 2 ).
Discussion
The results show that mutations at PBP2 551 (P551S/P551L) and 542 (G542S) are significantly associated with reduced susceptibility to ceftriaxone and resistance to penicillin in a panel of 98 temporally and geographically diverse gonococci, as well as being overrepresented in a recent selection (2007 -08) of gonococci exhibiting reduced susceptibility to ceftriaxone. In a recent study of crystal structures of gonococcal PBP2, Powell et al. 6 observed that two mutations, F504L and, in particular, P551S, were mainly responsible for decreasing penicillin acylation rates. This provides a possible functional basis for the significant associations observed with P551S/P551L in our clinical N. gonorrhoeae isolates. To our knowledge, G542S has not previously been specifically implicated as a gonococcal resistance mechanism. However, G542S in addition to P551S/P551L have consistently been observed, but not remarked upon, in previous studies investigating reduced susceptibility to ESCs in gonococci. For example, Ito et al.
2 examined the penA sequences of 70 Japanese N. gonorrhoeae isolates from 2001, observed 10 different PBP2 amino acid sequences and found that mosaic penA (PBP2 pattern X) comprised the majority of isolates exhibiting reduced susceptibility to ceftriaxone. Upon re-examining these data, it can be seen that all isolates harbouring mutations at positions 542 (PBP2 patterns IV, V, VII and VIII) and 551 (PBP2 patterns VI, VIII and IX) have ceftriaxone MICs ≥0.015 mg/L. Similarly, data from a 2007 Swedish study 4 show that both 542 and 551 mutations were well represented in N. gonorrhoeae lacking mosaic penA and exhibiting reduced susceptibility to ceftriaxone (0.064 -0.094 mg/L). More recently, data from a study of Korean gonococci showed that isolates with mutations at positions 542 (PBP2 patterns IV, V, XVII and XXIV) and 551 (PBP2 patterns XII, VIII and IX) all exhibited reduced susceptibility to ceftriaxone (MICs≥ 0.064 mg/L). 8 Further studies, including transformation experiments, are needed to investigate the precise and relative roles played by these mutations. However, in 12 of 76 non-mosaic-PBP2-containing gonococci examined in this study, neither these nor the mosaic penA lesion were detected, suggesting that other, as yet unknown, genetic mechanisms mediate increases in ESC MICs. To date, these genetic changes, although associated with in vitro increases in ceftriaxone MICs, have not been detected in gonococci isolated from treatment failures with this antibiotic.
Conclusions
It is well established that combinations of mosaic PBP2 and polymorphisms in mtrR and PorBIb, although prominently involved, cannot explain all the increases in ceftriaxone MICs documented thus far for N. gonorrhoeae. 7 Our findings provide strong evidence for the association of additional mutations in PBP2, particularly P551S/P551L, but also G542S, in conferring reduced susceptibility to ceftriaxone, as well as resistance to penicillin. Gonococcal PBP2 mutations
